Ahmed Adel Mohamed Alaa Eldin <br/><br/>
A pharmaceutical study on certain modified release etodolac dosage forms /  
 دراسة صيدلية على بعض الأشكال الصيدلية محورة الأنطلاق لعقار الإيتودولاك 
Ahmed Adel Mohamed Alaa Eldin ; Supervised Ahmed Abdelbary Abdelrahman , Mina Ibrahim Tadros 
 - Cairo :   Ahmed Adel Mohamed Alaa Eldin ,   2010 
 - 200 P. :   charts ;   25cm 
<br/><br/>Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics 
<br/><br/> Etodolac is non - steroidal anti - inflammatory drug acting by a preferential inhibition of cyclo - oxygenase - 2 ( COX - 2 ) enzyme . It is used for rheumatoid arthritis , including juvenile idiopathic arthritis , osteoathritis and for the treatment of acute pain . It has an elimination half - life of 7 hour and the recommended oral dose , 200 to 400 mg, is given every 6 to 8 hours to a maximum of 1.2 g daily , therefore it is a potential cadidate for controlled release formulations 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Controlled porosity osmotic pump ( CPOP ) tablets  Controlled release lipid matrix tablets  Etodolac